Cargando…

Interfractional target changes in brain metastases during 13-fraction stereotactic radiotherapy

BACKGROUND: The risk for radiation necrosis is lower in fractionated stereotactic radiotherapy (SRT) than in conventional radiotherapy, and 13-fraction SRT is our method of choice for the treatment of brain metastases ≥ around 2 cm or patients who are expected to have a good prognosis. As 13-fractio...

Descripción completa

Detalles Bibliográficos
Autores principales: Uto, Megumi, Ogura, Kengo, Katagiri, Tomohiro, Takehana, Keiichi, Mizowaki, Takashi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8317405/
https://www.ncbi.nlm.nih.gov/pubmed/34321033
http://dx.doi.org/10.1186/s13014-021-01869-4
_version_ 1783730064393764864
author Uto, Megumi
Ogura, Kengo
Katagiri, Tomohiro
Takehana, Keiichi
Mizowaki, Takashi
author_facet Uto, Megumi
Ogura, Kengo
Katagiri, Tomohiro
Takehana, Keiichi
Mizowaki, Takashi
author_sort Uto, Megumi
collection PubMed
description BACKGROUND: The risk for radiation necrosis is lower in fractionated stereotactic radiotherapy (SRT) than in conventional radiotherapy, and 13-fraction SRT is our method of choice for the treatment of brain metastases ≥ around 2 cm or patients who are expected to have a good prognosis. As 13-fraction SRT lasts for at least 17 days, adaptive radiotherapy based on contrast-enhanced mid-treatment magnetic resonance imaging (MRI) is often necessary for patients undergoing 13-fraction SRT. In this study, we retrospectively analyzed interfractional target changes in patients with brain metastases treated with 13-fraction SRT. METHODS: Our analyses included data from 23 patients and 27 metastatic brain lesions treated with 13-fraction SRT with dynamic conformal arc therapy. The peripheral dose prescribed to the planning target volume (PTV) was 39–44.2 Gy in 13-fractions. The gross tumor volume (GTV) of the initial SRT plan (initial GTV), initial PTV, and modified GTV based on the mid-treatment MRI scan (mid-treatment GTV) were assessed. RESULTS: The median initial GTV was 3.8 cm(3) and the median time from SRT initiation to the mid-treatment MRI scan was 6 days. Compared to the initial GTV, the mid-treatment GTV increased by more than 20% in five lesions and decreased by more than 20% in five lesions. Interfractional GTV volume changes of more than 20% were not significantly associated with primary disease or the presence of cystic components/necrosis. The mid-treatment GTV did not overlap perfectly with the initial PTV in more than half of the lesions. CONCLUSIONS: Compared to the initial GTV, the mid-treatment GTV changed by more than 20% in almost one-third of lesions treated with 13-fraction SRT. As SRT usually generates a steep dose gradient as well as increasing the maximum dose of PTV compared to conventional radiotherapy, assessment of the volume and locational target changes and adaptive radiotherapy should be considered as the number of fractions increases.
format Online
Article
Text
id pubmed-8317405
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-83174052021-07-30 Interfractional target changes in brain metastases during 13-fraction stereotactic radiotherapy Uto, Megumi Ogura, Kengo Katagiri, Tomohiro Takehana, Keiichi Mizowaki, Takashi Radiat Oncol Research BACKGROUND: The risk for radiation necrosis is lower in fractionated stereotactic radiotherapy (SRT) than in conventional radiotherapy, and 13-fraction SRT is our method of choice for the treatment of brain metastases ≥ around 2 cm or patients who are expected to have a good prognosis. As 13-fraction SRT lasts for at least 17 days, adaptive radiotherapy based on contrast-enhanced mid-treatment magnetic resonance imaging (MRI) is often necessary for patients undergoing 13-fraction SRT. In this study, we retrospectively analyzed interfractional target changes in patients with brain metastases treated with 13-fraction SRT. METHODS: Our analyses included data from 23 patients and 27 metastatic brain lesions treated with 13-fraction SRT with dynamic conformal arc therapy. The peripheral dose prescribed to the planning target volume (PTV) was 39–44.2 Gy in 13-fractions. The gross tumor volume (GTV) of the initial SRT plan (initial GTV), initial PTV, and modified GTV based on the mid-treatment MRI scan (mid-treatment GTV) were assessed. RESULTS: The median initial GTV was 3.8 cm(3) and the median time from SRT initiation to the mid-treatment MRI scan was 6 days. Compared to the initial GTV, the mid-treatment GTV increased by more than 20% in five lesions and decreased by more than 20% in five lesions. Interfractional GTV volume changes of more than 20% were not significantly associated with primary disease or the presence of cystic components/necrosis. The mid-treatment GTV did not overlap perfectly with the initial PTV in more than half of the lesions. CONCLUSIONS: Compared to the initial GTV, the mid-treatment GTV changed by more than 20% in almost one-third of lesions treated with 13-fraction SRT. As SRT usually generates a steep dose gradient as well as increasing the maximum dose of PTV compared to conventional radiotherapy, assessment of the volume and locational target changes and adaptive radiotherapy should be considered as the number of fractions increases. BioMed Central 2021-07-28 /pmc/articles/PMC8317405/ /pubmed/34321033 http://dx.doi.org/10.1186/s13014-021-01869-4 Text en © The Author(s) 2021 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Research
Uto, Megumi
Ogura, Kengo
Katagiri, Tomohiro
Takehana, Keiichi
Mizowaki, Takashi
Interfractional target changes in brain metastases during 13-fraction stereotactic radiotherapy
title Interfractional target changes in brain metastases during 13-fraction stereotactic radiotherapy
title_full Interfractional target changes in brain metastases during 13-fraction stereotactic radiotherapy
title_fullStr Interfractional target changes in brain metastases during 13-fraction stereotactic radiotherapy
title_full_unstemmed Interfractional target changes in brain metastases during 13-fraction stereotactic radiotherapy
title_short Interfractional target changes in brain metastases during 13-fraction stereotactic radiotherapy
title_sort interfractional target changes in brain metastases during 13-fraction stereotactic radiotherapy
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8317405/
https://www.ncbi.nlm.nih.gov/pubmed/34321033
http://dx.doi.org/10.1186/s13014-021-01869-4
work_keys_str_mv AT utomegumi interfractionaltargetchangesinbrainmetastasesduring13fractionstereotacticradiotherapy
AT ogurakengo interfractionaltargetchangesinbrainmetastasesduring13fractionstereotacticradiotherapy
AT katagiritomohiro interfractionaltargetchangesinbrainmetastasesduring13fractionstereotacticradiotherapy
AT takehanakeiichi interfractionaltargetchangesinbrainmetastasesduring13fractionstereotacticradiotherapy
AT mizowakitakashi interfractionaltargetchangesinbrainmetastasesduring13fractionstereotacticradiotherapy